Welcome to our website. It's always a work in progress and your feedback is welcome



Research Articles and Papers on:


Therapeutic Administration of 131I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies

Jérôme-Philippe Garsi, Martin Schlumberger, Carole Rubino, Marcel Ricard, Martine Labbé, Claudia Ceccarelli, Claire Schvartz, Michel Henri-Amar, Stéphane Bardet and Florent de Vathaire
Journal of Nuclear Medicine 2008;18:854-52

This study looked at pregnancy outcome and the health of children of women previously exposed to radioiodine (131I) (RAI) during thyroid cancer treatment.   

Female patients who were treated for thyroid cancer but had not received significant external radiation to the ovaries  were interviewed and data on 2,673 pregnancies was obtained.

The results showed that the incidence of miscarriages was 10% before any treatment for thyroid cancer; but increased after surgery for thyroid cancer, both before (20%) and after (19%) 131I treatment.  In contrast to previously reported data, miscarriages were not significantly more frequent in women treated with RAI during the year before conception, not even in women who had received more than 370 MBq during that year. The incidences of stillbirths, preterm births, low birth weight, congenital malformations, and death during the first year of life were not significantly different before and after RAI therapy and thyroid and nonthyroid cancers were similar in children born either before or after the mother's exposure to radioiodine. The researchers found no evidence that exposure to radioiodine affects the outcomes of subsequent pregnancies and children. However, they felt that the value of 1 Gy as the dose in humans should be re-evaluated.